1,718 Charles River Laboratories International, Inc. $CRL Shares Sold by Inscription Capital LLC

Inscription Capital LLC reduced its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 50.8% in the third quarter, HoldingsChannel reports. The institutional investor owned 1,665 shares of the medical research company’s stock after selling 1,718 shares during the quarter. Inscription Capital LLC’s holdings in Charles River Laboratories International were worth $491,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Commonwealth Equity Services LLC grew its holdings in Charles River Laboratories International by 733.4% in the 3rd quarter. Commonwealth Equity Services LLC now owns 35,428 shares of the medical research company’s stock worth $10,452,000 after acquiring an additional 31,177 shares during the last quarter. Virtue Capital Management LLC purchased a new position in shares of Charles River Laboratories International in the third quarter valued at about $278,000. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Charles River Laboratories International by 6.3% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,869 shares of the medical research company’s stock valued at $846,000 after acquiring an additional 170 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Charles River Laboratories International during the third quarter valued at about $7,399,000. Finally, Vise Technologies Inc. raised its stake in shares of Charles River Laboratories International by 58.9% during the third quarter. Vise Technologies Inc. now owns 3,831 shares of the medical research company’s stock valued at $1,130,000 after acquiring an additional 1,420 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on CRL shares. Royal Bank Of Canada increased their target price on shares of Charles River Laboratories International from $322.00 to $352.00 and gave the stock an “outperform” rating in a report on Thursday. Barclays upped their price target on Charles River Laboratories International from $330.00 to $375.00 and gave the company an “overweight” rating in a research report on Thursday. CLSA cut Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective for the company. in a report on Monday, July 20th. Jefferies Financial Group increased their price objective on Charles River Laboratories International from $305.00 to $340.00 and gave the stock a “buy” rating in a report on Monday, September 28th. Finally, TD Cowen lifted their price objective on Charles River Laboratories International from $300.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday, September 25th. Thirteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and a consensus target price of $308.17.

Charles River Laboratories International Price Performance

CRL stock opened at $337.91 on Friday. Charles River Laboratories International, Inc. has a 1 year low of $146.20 and a 1 year high of $379.63. The company has a market cap of $16.19 billion, a P/E ratio of 371.33, a PEG ratio of 3.14 and a beta of 1.36. The firm has a 50-day moving average of $305.71 and a 200 day moving average of $225.19. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.41 and a quick ratio of 1.04.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, beating the consensus estimate of $2.97 by $0.12. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The business had revenue of $982.73 million for the quarter, compared to analysts’ expectations of $960.36 million. During the same period in the previous year, the firm posted $2.43 EPS. The business’s revenue was down 2.2% on a year-over-year basis. On average, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 11.44 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In related news, EVP Shannon M. Parisotto sold 3,714 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $279.66, for a total value of $1,038,657.24. Following the sale, the executive vice president directly owned 4,807 shares of the company’s stock, valued at $1,344,325.62. This represents a 43.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Birgit Girshick sold 6,500 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the completion of the transaction, the chief executive officer owned 36,013 shares of the company’s stock, valued at approximately $10,080,038.70. This trade represents a 15.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 102,299 shares of company stock worth $31,050,863. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support.

The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions.